Elisabetta Munzone

8.2k total citations
129 papers, 3.3k citations indexed

About

Elisabetta Munzone is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Elisabetta Munzone has authored 129 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Oncology, 73 papers in Cancer Research and 45 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Elisabetta Munzone's work include Breast Cancer Treatment Studies (59 papers), Cancer Treatment and Pharmacology (42 papers) and HER2/EGFR in Cancer Research (35 papers). Elisabetta Munzone is often cited by papers focused on Breast Cancer Treatment Studies (59 papers), Cancer Treatment and Pharmacology (42 papers) and HER2/EGFR in Cancer Research (35 papers). Elisabetta Munzone collaborates with scholars based in Italy, United States and Switzerland. Elisabetta Munzone's co-authors include Marco Colleoni, Franco Nolè, Giuseppe Curigliano, Aron Goldhirsch, Laura Adamoli, Giuseppe Capri, Nicole Rotmensz, Luca Gianni, Giuseppe Viale and Aron Goldhirsch and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Elisabetta Munzone

120 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elisabetta Munzone Italy 31 2.4k 1.4k 765 611 302 129 3.3k
T. Delozier France 30 3.3k 1.4× 1.7k 1.2× 987 1.3× 568 0.9× 296 1.0× 92 4.3k
Mario Giuliano Italy 34 2.4k 1.0× 1.4k 1.0× 1.2k 1.5× 1.0k 1.6× 328 1.1× 109 3.8k
G. N. Hortobágyi United States 23 1.7k 0.7× 962 0.7× 543 0.7× 573 0.9× 253 0.8× 106 2.7k
Carla I. Falkson United States 26 1.8k 0.8× 797 0.6× 528 0.7× 811 1.3× 316 1.0× 95 2.8k
Andrea Rocca Italy 33 2.3k 0.9× 1.3k 0.9× 911 1.2× 1.1k 1.8× 413 1.4× 135 4.1k
Angela Moliterni Italy 21 2.1k 0.9× 1.7k 1.2× 396 0.5× 321 0.5× 305 1.0× 35 3.0k
Anne O’Neill United States 30 1.8k 0.8× 979 0.7× 822 1.1× 505 0.8× 211 0.7× 89 3.5k
Romano Demicheli Italy 33 2.1k 0.9× 1.3k 0.9× 546 0.7× 710 1.2× 153 0.5× 97 3.4k
K. Hacène France 26 1.7k 0.7× 1.2k 0.9× 661 0.9× 881 1.4× 301 1.0× 76 3.2k
Yeon Hee Park South Korea 34 2.5k 1.0× 1.5k 1.1× 1.3k 1.7× 1.1k 1.9× 486 1.6× 196 4.1k

Countries citing papers authored by Elisabetta Munzone

Since Specialization
Citations

This map shows the geographic impact of Elisabetta Munzone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabetta Munzone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabetta Munzone more than expected).

Fields of papers citing papers by Elisabetta Munzone

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabetta Munzone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabetta Munzone. The network helps show where Elisabetta Munzone may publish in the future.

Co-authorship network of co-authors of Elisabetta Munzone

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabetta Munzone. A scholar is included among the top collaborators of Elisabetta Munzone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabetta Munzone. Elisabetta Munzone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Milano, Monica, Nadia Bianco, Carmine Valenza, et al.. (2025). 336P Approaches for locoregional optimization in oligometastatic and oligopersistent metastatic breast cancer. ESMO Open. 10. 104908–104908.
2.
Rediti, Mattia, David Venet, Samira Majjaj, et al.. (2023). Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00. Clinical Cancer Research. 29(23). 4908–4919. 7 indexed citations
3.
Venetis, Konstantinos, Francesco Pepe, Elham Sajjadi, et al.. (2023). Abstract P6-04-14: Comparison of next-generation sequencing and real-time PCR for PIK3CA testing in hormone receptor-positive/HER2-negative breast cancer on metastatic and matched primary tumor samples. Cancer Research. 83(5_Supplement). P6–4. 1 indexed citations
4.
Zambelli, Alberto, Marina Elena Cazzaniga, Nicla La Verde, et al.. (2023). A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy. The Breast. 71. 113–121. 2 indexed citations
5.
Ferrando, Lorenzo, Andrea Vingiani, Anna Garuti, et al.. (2023). ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). PLoS Genetics. 19(1). e1010563–e1010563. 7 indexed citations
6.
Corso, Giovanni, Sabrina Kahler Ribeiro Fontana, Eleonora Pagan, et al.. (2021). Ten‐year outcome results of cT4 breast cancer after neoadjuvant treatment. Journal of Surgical Oncology. 124(8). 1242–1250. 4 indexed citations
7.
Schmid, Sabine, Dirk Klingbiel, Stefan Aebi, et al.. (2019). Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. BMC Cancer. 19(1). 902–902. 7 indexed citations
8.
Cazzaniga, Marina Elena, Elisabetta Munzone, Guido Bocci, et al.. (2018). Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project. Advances in Therapy. 36(2). 381–406. 23 indexed citations
9.
Montagna, Emilia, Antonella Palazzo, Patrick Maisonneuve, et al.. (2017). Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial. Cancer Letters. 400. 276–281. 32 indexed citations
10.
Munzone, Elisabetta. (2016). ecancermedicalscience. ecancermedicalscience. 8. 426–426. 6 indexed citations
11.
Munzone, Elisabetta, Cecilia Casali, Gaetano Aurilio, et al.. (2016). ecancermedicalscience. ecancermedicalscience. 7. 309–309. 1 indexed citations
12.
Munzone, Elisabetta & Marco Colleoni. (2015). Clinical overview of metronomic chemotherapy in breast cancer. Nature Reviews Clinical Oncology. 12(11). 631–644. 104 indexed citations
13.
Aurilio, Gaetano, Vincenzo Bagnardi, Rossella Graffeo, et al.. (2014). Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?. PubMed. 34(11). 6677–83. 15 indexed citations
14.
Aurilio, Gaetano, Davide Disalvatore, Giancarlo Pruneri, et al.. (2013). A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. European Journal of Cancer. 50(2). 277–289. 199 indexed citations
15.
Aurilio, Gaetano, Lorenzo Monfardini, Stefania Rizzo, et al.. (2013). Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncologica. 52(8). 1649–1656. 55 indexed citations
16.
Colleoni, Marco & Elisabetta Munzone. (2013). Extended adjuvant chemotherapy in endocrine non-responsive disease. The Breast. 22. S161–S164. 4 indexed citations
17.
Munzone, Elisabetta, Edoardo Botteri, Maria Teresa Sandri, et al.. (2012). Prognostic Value of Circulating Tumor Cells According to Immunohistochemically Defined Molecular Subtypes in Advanced Breast Cancer. Clinical Breast Cancer. 12(5). 340–346. 38 indexed citations
18.
Munzone, Elisabetta, Attilio Di Pietro, Aron Goldhirsch, et al.. (2009). Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report. The Breast. 19(1). 33–37. 23 indexed citations
19.
Nolè, Franco, Chiara Catania, Elisabetta Munzone, et al.. (2006). Capecitabine/Vinorelbine: An Effective and Well-Tolerated Regimen for Women with Pretreated Advanced-Stage Breast Cancer. Clinical Breast Cancer. 6(6). 518–524. 25 indexed citations
20.
Curigliano, Giuseppe, Gianluca Spitaleri, Elisabetta Pietri, et al.. (2005). Breast cancer vaccines: a clinical reality or fairy tale?. Annals of Oncology. 17(5). 750–762. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T. Delozier Breakdown of academic impact, for papers by Mario Giuliano Breakdown of academic impact, for papers by G. N. Hortobágyi Breakdown of academic impact, for papers by Carla I. Falkson Breakdown of academic impact, for papers by Andrea Rocca Breakdown of academic impact, for papers by Angela Moliterni Breakdown of academic impact, for papers by Anne O’Neill Breakdown of academic impact, for papers by Romano Demicheli Breakdown of academic impact, for papers by K. Hacène Breakdown of academic impact, for papers by Yeon Hee Park
Rankless by CCL
2026